European Union Horizon 2020

Submitted by barbara on

Horizon 2020 is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020) – in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.

S-004992

Submitted by barbara on

Shionogi quarterly reports update from Oct 2019 stated that they returned the rights to S-004992 back to C&O due to pre-clinical study results. 

 

Shinonogi & Co., Ltd is developing S-004992 in collaboration with its originator C&O Pharmaceutical Technology (Holdings) Limited of China, a Shionogi’s subsidiary. Now in GLP studies, S-004992 may enter clinical studies in April 2020.

Gordon Research Conference: Shortening the Duration of Tuberculosis Chemotherapy

Submitted by zaidtanvir on

The 2019 Conference on Tuberculosis Drug Discovery and Development will feature presentations on breaking science in preclinical and clinical TB drug discovery and development. The talks will serve as primers for in-depth discussions on the unique challenges posed by TB relative to other infectious diseases, and topics will include how drug and target properties relate to efficacy in different models, and how these features might inform clinical trials to realize the goal of treatment shortening.

Pages

Subscribe to Working Group for New TB Drugs RSS